Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled corticosteroid (ICS) Clear all
Completed Phase 3 Interventional Results available

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

NCT05505734
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI, AS MDI
Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

NCT07288827
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Healthy
Interventions
Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

NCT01691547
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC /VI, UMEC, VI, FF
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01053988
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
47
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

NCT03860519
View directory record Official record
Conditions
Asthma
Interventions
Electronic Medication Monitors on ICS and SABA - Active Mode, Electronic Medication Monitors on ICS and SABA - Silent Mode, Asthma App Tracking of ICS/SABA Usage - Active Mode, Asthma App Tracking of ICS/SABA Usage - Silent Mode, NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes, NorthShore Connect Real Time ICS and SABA Usage Feedback - No, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
Behavioral
Lead sponsor
Endeavor Health
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 28, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

NCT04990167
View directory record Official record
Conditions
Asthma in Children
Interventions
Tiotropium Bromide
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Results available

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

NCT01881412
View directory record Official record
Conditions
Asthma
Interventions
fluticasone, Standard Asthma Discharge Instructions
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
3 Years to 12 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 4 Interventional

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

NCT02577497
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone, fluticasone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting No phase listed Observational

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

NCT07787117
View directory record Official record
Conditions
Asthma
Interventions
None (observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma

NCT05341726
View directory record Official record
Conditions
Asthma
Interventions
BREATHE Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Beacon, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial

NCT03907410
View directory record Official record
Conditions
Medication Adherence, Asthma in Children
Interventions
Nominal Financial Incentives, Daily Adherence Reminders/Adherence Performance Feedback
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD

NCT05607719
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Bevespi, Bretzri
Drug
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01054885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting Phase 4 Interventional

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942
View directory record Official record
Conditions
Asthma, Asthma Attack, Asthma Exacerbations
Interventions
Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
Drug · Other
Lead sponsor
DARTNet Institute
Government
Eligibility
13 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

NCT00294398
View directory record Official record
Conditions
Asthma
Interventions
ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

NCT01216735
View directory record Official record
Conditions
Tobacco Abuse Smoke
Interventions
Fluticasone, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 28, 2026, 10:12 AM EDT